Everything below concerns MC4 receptor. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-07-01. Numbers and descriptions here follow the published literature rather than marketing material.
Published studies examine a fairly narrow set of endpoints. Rodent experiments commonly measure maze learning, infarct volume after induced ischemia, and tissue levels of neurotrophic factors. Clinical reports from Russian centres describe attention, memory and recovery scores in patients after stroke or transient ischemic attack. Most of those human studies are small and few have been repeated by independent groups. Outcome measures differ between studies, which limits direct comparison.
Circulation time for the peptide is short because peptidases cleave it readily. The Pro-Gly-Pro tail is thought to slow breakdown compared with the bare ACTH fragment, but the gain appears modest. Absorption after intranasal dosing is limited, and only a fraction of a dose is expected to reach the central nervous system. Laboratory concentrations therefore sit well above levels achieved systemically, a gap that complicates translation from bench findings to clinical claims.
The mechanisms attributed to semax are inferred from animal and cell studies rather than traced to one confirmed target. The most frequently cited pathway involves increased expression of brain-derived neurotrophic factor and nerve growth factor in hippocampal and cortical tissue. Some work points to engagement of melanocortin receptors, particularly MC4, which the parent ACTH fragment can activate. Effects on dopaminergic and serotonergic signalling have also been reported. No single account explains all observed results, and the relative weight of each pathway remains unsettled.
Semax is a synthetic peptide created in the Soviet Union during the early 1980s by researchers working in Moscow. It was built from the short adrenocorticotropic hormone fragment known as ACTH(4-10), and the chain was then extended with three additional amino acids. The resulting molecule was named semax and entered clinical use in Russia in 1994. It is generally described as a nootropic and neuroprotective agent rather than as a hormone analogue.
The parent fragment ACTH(4-10) carries the sequence Met-Glu-His-Phe-Arg-Trp-Gly. Semax replaces the arginine and tryptophan positions with a proline-glycine-proline tail, giving Met-Glu-His-Phe-Pro-Gly-Pro. That change removes residues associated with adrenal stimulation, so the peptide does not drive cortisol release the way full ACTH does. This distinction shapes how the compound is grouped in the literature, where it sits with neuropeptides and peptide neuromodulators rather than with corticosteroids.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized solid from research suppliers |
| Solubility | Freely soluble in water | Also dissolves in aqueous buffers; solutions are used fresh |
| Typical storage temperature | -20 °C for lyophilized powder | Short-term transport at 2-8 °C is common |
| Common analytical method | Reverse-phase HPLC | Paired with mass spectrometry for identity confirmation |
| Common synonyms | ACTH(4-10) analogue; MEHFPGP | N-terminal methionine retained in the chain |
Common degradation pathways include oxidation of the methionine side chain, hydrolysis of the peptide backbone, and aggregation under unfavourable pH or concentration. Stability studies typically monitor the main peak by chromatography and report total related substances as a percentage. Because no official monograph exists, acceptance criteria vary between laboratories, and reported purity values are not directly comparable across suppliers. Analysts therefore document the method, column, and detection wavelength alongside each result, and open questions remain about how much biological activity the oxidised forms retain.
Solid semax is typically supplied as a lyophilised powder that is hygroscopic and sensitive to moisture, light, and repeated temperature cycling. Long-term storage of the dry peptide is generally recommended at approximately -20 degrees Celsius, while shorter working periods may use refrigeration at 2 to 8 degrees Celsius. Vials should remain tightly closed and desiccated when brought to room temperature, because condensation can damage the material before it is weighed. Dividing a batch into aliquots is preferable to thawing one container repeatedly.
Dissolution is normally performed in water, phosphate-buffered saline, or normal saline, since the peptide is freely soluble in aqueous media and is rarely handled with strong organic solvents. Solution pH should be kept near neutral, because extreme acidity or alkalinity accelerates backbone hydrolysis and encourages oxidation of the methionine side chain. Once dissolved, the material is less stable than the dry powder and is commonly divided into single-use portions and frozen. Buffers containing primary amines, such as Tris, are often avoided because of possible side reactions.
The compound was developed in the 1980s at the Institute of Molecular Genetics in Moscow, where it emerged from research on short ACTH fragments and their effects on the central nervous system. Russian pharmaceutical listings describe it as a nootropic and neuroprotective agent, most often formulated as nasal drops. It is not a marketed medicine in the United States or the European Union, and no pharmacopoeial monograph covers it. Consequently, most published clinical experience with the substance originates from a small number of research centres, mainly in Russia and neighbouring countries.
Pharmacological accounts link semax to melanocortin signalling and to modulation of neurotrophic factor expression, particularly brain-derived neurotrophic factor and nerve growth factor. Much of this evidence comes from rodent studies using intranasal delivery, a route chosen because it allows peptides to reach the central nervous system with limited systemic exposure. Whether the same mechanisms operate in humans at comparable magnitude remains an open question. The precise receptor or receptors responsible for the reported behavioural and neuroprotective effects have not been conclusively identified.
Clinical reports describe use in ischaemic stroke, transient ischaemic attack, optic nerve conditions, and cognitive complaints, but most of these studies are small and were conducted in a single region. Systematic reviews have generally described the evidence base as limited in size and variable in methodological quality. Randomised controlled data suitable for international regulatory assessment are scarce. As a result, major treatment guidelines outside Russia do not include the peptide, and interest in it remains largely research-driven rather than routine clinical.
Identity and purity are confirmed with reversed-phase high-performance liquid chromatography, typically monitored at 214 nanometres where the peptide bond absorbs. Mass spectrometry, either electrospray or MALDI-TOF, verifies molecular mass against the theoretical value and detects truncation or adduct formation. Amino acid analysis and peptide mapping provide additional confirmation when required. The most frequently reported impurities are deletion sequences from incomplete coupling, methionine sulfoxide from oxidation, and dimeric species formed through non-covalent aggregation. Impurity profiles depend strongly on the synthesis and purification route chosen by the producer.
Published research has focused mainly on neurological and cognitive endpoints in animal models, with proposed mechanisms involving brain-derived neurotrophic factor and related signalling pathways. A substantial share of the human data originates from a limited number of research groups, and independent replication in other countries remains sparse. Regulatory status reflects that distribution: the peptide is registered as a medicine in Russia and appears in some neighbouring markets, while elsewhere it is handled as a research chemical without approved therapeutic labelling. Questions about dose-response relationships, long-term effects, and comparability across studies are still open.
Lyophilised powder is normally kept at -20 °C in a desiccated container, with some suppliers recommending -80 °C for long-term archival storage. Repeated freeze-thaw cycles are the most common cause of avoidable loss, so aliquoting before freezing reduces variability between working sessions. Dissolved peptide is far less stable than the dry solid and is usually prepared fresh or held briefly at 4 °C. Aqueous solutions support both hydrolysis of the backbone and oxidation of the N-terminal methionine, and these two routes dominate degradation under ordinary laboratory conditions.
Terminology around the compound varies by source. It appears in catalogues and papers as Semax, as the heptapeptide ACTH(4-7)-Pro-Gly-Pro, and under various alphanumeric laboratory codes used by individual suppliers. These names refer to the same sequence but may imply different salt forms, purity grades, or counter-ions. Peptide databases usually list the free base mass, while product descriptions sometimes report acetate or trifluoroacetate salts with a different formula weight. Because naming conventions for research peptides are not standardised across vendors, checking the declared sequence and measured mass is more reliable than relying on a trade name alone.
Semax is a synthetic heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. Its design combines the ACTH(4-7) core fragment with a C-terminal Pro-Gly-Pro extension, a modification intended to improve stability and prolong activity. The molecule is hydrophilic, carries no lipid chains or glycosylation, and has a theoretical mass just over 810 daltons in its free form. All seven residues are proteinogenic amino acids, so no non-natural building blocks appear in the backbone. A free N-terminal methionine and C-terminal proline define the unmodified parent peptide.
The compound was developed during the 1980s at the Institute of Molecular Genetics in Moscow as part of research on fragments of adrenocorticotropic hormone. Early work examined short ACTH-derived sequences that retained neurotrophic effects while lacking the endocrine activity of the full hormone. Semax entered clinical use in Russia during the 1990s, where it received registration for several neurological indications. Outside that region it remained primarily a laboratory research material rather than an approved therapeutic. English-language literature on it grew more slowly and frequently cited the original Russian studies.
Football is the most popular sport in Germany. With more than 7 million official members, the German Football Association (Deutscher Fußball-Bund) is the largest single-sport organisation worldwide, and the German top league, the Bundesliga, attracts the second-highest average attendance of all professional sports leagues in the world. The German men's national football team won the FIFA World Cup in 1954, 1974, 1990, and 2014, the UEFA European Championship in 1972, 1980 and 1996, and the FIFA Confederations Cup in 2017. Germany is one of the world's leading motor sports countries, with constructors such as BMW and Mercedes playing prominent roles in international competition. Porsche has won the 24 Hours of Le Mans race 19 times, and Audi 13 times, as of April 2024. The driver Michael Schumacher has set many motor sport records, having won seven Formula One World Drivers' Championships. Sebastian Vettel is also among the most successful Formula One drivers of all time. German athletes historically have been successful contenders in the Olympic Games, ranking third in an all-time Olympic Games medal count when combining East and West German medals prior to German reunification. In 1936, Berlin hosted the Summer Games and the Winter Games in Garmisch-Partenkirchen. Munich hosted the Summer Games of 1972.
After this period, they are able to advance to registrar grade when they undergo a compulsory subspecialty training (including acute internal medicine or a dual subspecialty including internal medicine). This latter stage of training is achieved through competition rather than just by yearly progress as the first years of postgraduate training.
Pyrolysis can also be used to treat municipal solid waste and plastic waste. The main advantage is the reduction in volume of the waste. In principle, pyrolysis will regenerate the monomers (precursors) to the polymers that are treated, but in practice the process is neither a clean nor an economically competitive source of monomers. In tire waste management, tire pyrolysis is a well-developed technology. Other products from car tire pyrolysis include steel wires, carbon black and bitumen. The area faces legislative, economic, and marketing obstacles. Oil derived from tire rubber pyrolysis has a high sulfur content, which gives it high potential as a pollutant; consequently it should be desulfurized. Alkaline pyrolysis of sewage sludge at low temperature of 500 °C can enhance H2 production with in-situ carbon capture. The use of NaOH (sodium hydroxide) has the potential to produce H2-rich gas that can be used for fuels cells directly. In early November 2021, the U.S. State of Georgia announced a joint effort with Igneo Technologies to build an $85 million large electronics recycling plant in the Port of Savannah. The project will focus on lower-value, plastics-heavy devices in the waste stream using multiple shredders and furnaces using pyrolysis technology. Waste from pyrolysis itself can also be used for useful products.
Sources: en.wikipedia.org
During total overcast, the amount of absorption due to clouds is heavily dependent on the thickness of the clouds and latitude, with no clear measurements correlating specific thickness and absorption of UVA and UVB. The shorter bands of UVC, as well as even more-energetic UV radiation produced by the Sun, are absorbed by oxygen and generate the ozone in the ozone layer when single oxygen atoms produced by UV photolysis of dioxygen react with more dioxygen. The ozone layer is especially important in blocking most UVB and the remaining part of UVC not already blocked by ordinary oxygen in air.
Badly decomposing bodies, trauma cases, frozen, or drowned bodies, and those to be transported over long distances also require special treatment beyond that for the "normal" case. The restoration of bodies and features damaged by accident or disease is commonly called restorative art or demisurgery, and all qualified embalmers have some degree of training and practice in it. For such cases, the benefit of embalming is startlingly apparent. Normally, a better result can be achieved when a photograph and the decedent's regular make-up (if worn) are available to help make the deceased appear more as they did when alive. Embalming autopsy cases differs from standard embalming because the nature of the post-mortem examination irrevocably disrupts the circulatory system, due to the removal of the organs and viscera. In these cases, a six-point injection is made through the two iliac or femoral arteries, subclavian or axillary vessels, and common carotids, with the viscera treated separately with cavity fluid or a special embalming powder in a viscera bag. Long-term preservation requires different techniques, such as using stronger preservatives and multiple injection sites to ensure thorough saturation of body tissues.
During the Islamic Golden Age under the Abbasid Caliphate, prominent Muslim physicians preserved, systematized and developed ancient medical knowledge from across the Eurasian continent. They synthesized concepts from classical antiquity (see: Ancient Greece, Ancient Rome), Persia, Ayurveda, and China. This work laid the foundations for later advances in medieval European medicine as European physicians came into contact with Islamic authors through the Renaissance of the 12th century. Rhazes (c. 865–925), or Muhammad ibn Zakariya al-Razi, included writings about diabetes in the more than 230 books he produced in his lifetime. Avicenna (980–1037), or Ibn Sina, was a court physician to the caliphs of Baghdad and a key figure in medicine who compiled an exhaustive medical encyclopedia titled The Canon of Medicine. His account detailed the clinical features of diabetes, and termed the disease albulab ("water wheel") and zalkh el kuliah ("diarrhea of the kidneys"). He documented "the abnormal appetite and the collapse of sexual functions" and the sweet taste of diabetic urine, and further differentiated diabetes associated with emaciation from other causes of polyuria. He also elaborated on diabetic gangrene and treated diabetes using a mixture of lupine, trigonella (fenugreek), and zedoary seed. It has been noted that references to diabetes expanded in the medical texts of this period. Eknoyan and Nagy (2005) speculate that this indicates the increasing prevalence of the disease.
== Prevalence and popularity == Globally, 14.3% of married or partnered women of reproductive age (15–49) use intrauterine contraception as their preferred method of family planning. A study found that female family planning providers choose LARC methods more often (41.7%) than the general public (12.1%). However, the adoption of IUDs varies significantly across different regions. In Asia, IUD is particularly popular, with 27% of contraceptive users relying on it, while in Oceania, the usage rate is much lower at 1.8%. Geographically, the majority of IUD users—over 80% worldwide—are concentrated in Asia, with nearly two-thirds (64%) of these users living in China, according to a 2011 United Nations review. IUD use is more prevalent in less developed regions (15.1% of women) compared to more developed regions (9.2% of women). Within continents, there are significant variations. For instance, in Europe, IUD use ranges from 5% in Southern Europe to 16–28% in countries like France and Scandinavia. In Africa, IUD use is relatively low in sub-Saharan regions (less than 2%) but higher in Northern Africa, particularly in countries such as Egypt (36.1%) and Tunisia (27.8%). In the United States, the use of IUDs increased from 0.8% in 1995 to 7.2% from the period of 2006 to 2014 and to 10.5% in a 2017-2019 survey. IUD usage rates are also influenced by ethnicity within the United States, with Hispanic women more likely to use IUD compared to Caucasian women. Among birth control methods, IUDs, along with other contraceptive implants, result in the greatest satisfaction among users.
Sources: en.wikipedia.org
It consists mainly of animal experiments and small clinical reports, with much of the clinical material published in Russian-language journals. Large independent trials are scarce. Separating reliable effects from chance findings is consequently difficult.
A fraction of an intranasal dose is thought to reach the central nervous system, and this route is favoured partly for that reason. The proportion is not well characterized. Direct measurement in humans remains difficult with current methods.
Raised BDNF and NGF expression has been reported across several animal studies, which makes the signal fairly consistent. Whether the same change occurs in humans at usable doses is not established. It is best treated as a working hypothesis rather than a confirmed clinical mechanism.
Registered medical products are most often 0.1% nasal drops. Research suppliers ship lyophilized powder, usually in milligram quantities, which is dissolved before use. The active peptide is the same in both cases; presentation and excipients differ.